The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling

Obesity and nonalcoholic fatty liver disease (NAFLD) are global health concerns, and thus, drugs for the long-term treatment of these diseases are urgently needed. We previously discovered that the inositol pyrophosphate biosynthetic enzyme IP6K1 is a target in diet-induced obesity (DIO), insulin re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Sandip, Chakraborty, Molee, Haubner, Jake, Ernst, Glen, DePasquale, Michael, Carpenter, Danielle, Barrow, James C., Chakraborty, Anutosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216446/
https://www.ncbi.nlm.nih.gov/pubmed/37238737
http://dx.doi.org/10.3390/biom13050868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216446/
https://www.ncbi.nlm.nih.gov/pubmed/37238737
http://dx.doi.org/10.3390/biom13050868

Ejemplares similares